Comparative Pharmacology
Head-to-head clinical analysis: INDOMETHACIN versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDOMETHACIN versus PROFENAL.
INDOMETHACIN vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
25-50 mg orally 2-3 times daily; maximum 200 mg/day. Also available as 75 mg sustained-release capsule orally once daily, or 50 mg rectally 3-4 times daily.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 4.5 hours (range 2.6-11.2 hours) in adults; prolonged in neonates (up to 17 hours) and in patients with renal impairment or cholestasis; clinical context: dosing interval adjustments needed in hepatic or renal disease.
Clinical Note
moderateIndomethacin + Gatifloxacin
"Indomethacin may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIndomethacin + Rosoxacin
"Indomethacin may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIndomethacin + Levofloxacin
"Indomethacin may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIndomethacin + Trovafloxacin
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Renal excretion of unchanged drug and metabolites (approximately 60% as parent drug and glucuronide conjugate; 23% as O-desmethyl metabolite; 13% as glucuronide of O-desmethyl metabolite); biliary/fecal elimination accounts for 30-40%, primarily as glucuronide conjugates.
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category D/X
Category C
NSAID
NSAID
"Indomethacin may increase the neuroexcitatory activities of Trovafloxacin."